Methylene blue versus vasopressin analog for refractory septic shock in the preterm neonate: A randomized controlled trial

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner) and Vasopressin, published as a randomized controlled trial.

This study aims to assess the vasopressor effect of methylene blue (MB) in comparison to terlipressin (TP) as adjuvant therapy for refractory septic shock in the preterm neonate.

Who Took Part

PubMed indexes the participants as infants.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.

A double-blinded randomized controlled trial was conducted in the Neonatal Intensive Care Units at Ain Shams University, Egypt.

Thirty preterm neonates with refractory septic shock were randomized to receive either MB or TP as an adjuvant to conventional therapy.

The hemodynamic variables, functional echocardiographic variables, and oxidant stress marker were assessed over a 24 h period together with the side effects of MB.

What Was Measured

Topics PubMed links to this paper include Hemodynamics, Infant, Premature, Methylene Blue, Shock, Septic, Terlipressin, Vasoconstrictor Agents and Vasopressins.

Author keywords: neonate and septic shock.

What This Means in Plain Language

The paper is a randomized and double-blind study of Methylene blue (non-peptide stack partner) and Vasopressin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Journal of neonatal-perinatal medicine), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page and the Vasopressin compound page.